AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06762145
Drug: Methylprednisolone (Corticosteroid)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Methylprednisolone 1mg/kg/d for 3 days started from the day on TAVR
Trial: NCT05680298
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: solution for injection, Subcutaneous injection
Trial: NCT06773143
Drug: Esketamine at low dose
RxNorm normalized name: esketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After the induction of general anesthesia, patients in the esketamine group will receive a continuous infusion of esketamine (0.3 mg/kg/h) until the end of the operation.
Trial: NCT05578846
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally with a high-fat meal.
Trial: NCT05427695
Drug: Lactobacillus sakei proBio65
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanto Sinus probiotic Lactobacillus sakei is a currently available over the counter supplement from the common source kimchi and produced in South Korea. Patients will be instructed to mix 1 packet with lukewarm distilled or boiled water in 240mL NeilMed® sinus rinse bottle.
Trial: NCT04339036
Drug: Temozolomide Oral Product
RxNorm normalized name: temozolomide Oral Product
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: temozolomide 200 mg/m2 orally on Days 10-14, with 14 days between cycles
Trial: NCT04531046
Drug: axicabtagene ciloleucel
RxNorm normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-specific (autologous) product cryopreserved in cryostorage bag
Trial: NCT06582745
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will be given trametinib as a single agent once a day dosing, with a maximum dose of 2kg. Participants who are able to swallow pills will be given oral tablets. Participants unable to swallow pills will be dispensed the liquid formula concentrate at 0.05mg/mL with dosing of 0.015mg/kg.
Trial: NCT06156332
Drug: surufatinib、serplulimab
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: surufatinib:~250 mg (5 capsules) once a day, Q3W, continued until the patient developed disease progression or met other protocol criteria for discontinuation of study treatment; If the patient vomits after taking the medicine, there is no need to take the supplement; The missed dose should not be added the next day, and the next prescribed dose should be taken as usual.~serplulimab:~300mg fixed dose, intravenous infusion, d1, Q3W; Continued administration until the patient developed disease progression or met other protocol criteria for discontinuation of study therapy.~Imaging was used every 6 weeks (±7 days) to evaluate tumor status until disease progression (RECIST 1.1) or death (during patient treatment), and tumor treatment and survival status after disease progression were recorded. The changes of neuroendocrine tumor markers were detected after treatment.
Trial: NCT05366166
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the induction phase, participants will receive daily oral olaparib 150 mg two times a day for 3 weeks prior to chemoradiotherapy. In the Maintenance Phase, participants will receive daily olaparib 150 mg two times a day for up to 48 weeks.
Trial: NCT05366166
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the chemoradiation phase, participants will receive weekly intravenous cisplatin infusion, 40 mg/m2 over 7 weeks.~In the chemoradiation phase, standard of care radiation therapy and chemotherapy will be administered, for a total of 7 weeks. Radiation therapy is done on daily basis (excluding weekends), and chemotherapy therapy will involve cisplatin infusion once weekly.
Trial: NCT05754450
Drug: AVTX-803
DrugBank: VTX-803 (DB18271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-fucose crystalline powder
Trial: NCT06056141
Drug: Misoprostol 200mcg Tab
RxNorm normalized name: MISOPROSTOL 200MCG TAB
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 200 mcg dissolvedwith 200 ml water and divided to 25ml solution every 2 hours per os for maximum of 8 doses
Trial: NCT06735781
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As prescribed by the treating clinician
Trial: NCT04669171
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: D1-21 of 4-weekly cycles
Trial: NCT06754332
Drug: human chorionic gonadotropin
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The POI patients receive a single intramuscular injection of 10,000 units of human chorionic gonadotropin.
Trial: NCT06754761
Drug: AZD6738 / ceralasertib
DrugBank: Ceralasertib (DB14917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase ATR
Trial: NCT06423703
Drug: Cebranopadol
RxNorm normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily for 3 days
Trial: NCT06423703
Drug: Oxycodone IR
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: four times per day for 3 days
Trial: NCT06309953
Drug: Miebo
RxNorm normalized name: Miebo
DrugBank: Perfluorohexyloctane (DB17823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miebo treatment
Trial: NCT06757907
Drug: Acyclovir 400 MG
RxNorm normalized name: acyclovir 400 MG
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir is used to treat infections caused by certain types of viruses.
Trial: NCT06757907
Drug: Ganciclovir (GCV)
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir is an anti-viral drug
Trial: NCT06685718
Drug: BG-60366
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06761092
Drug: Nebulized Dexmedetomidine for Post-Anesthesia Delirium in Preschool Children
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulization with the anesthetic drug dexmedetomidine at a dose of 2 mcg/kg body weight, diluted to 3 ml with 0.9% normal saline, administered before the induction of anesthesia in the reception area.~After the anesthesia, primary data collection is conducted by recovery room staff who are blinded to the treatment and control groups. Data includes scores or levels of post-anesthesia delirium or agitation assessed using the PAED score at 15, 30, 60, and 120 minutes post-surgery in the recovery room
Trial: NCT06761027
Drug: Anlotinib combined with Sintilimab
RxNorm normalized name: miconazole
DrugBank: Anlotinib (DB11885)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Based on the mFOLFIRINOX chemotherapy regimen, combined with the safe dose of anlotinib determined in phase Ib and sintilimab.
Trial: NCT06794593
Drug: Camostat Mesylate
RxNorm normalized name: camostat mesylate
DrugBank: Camostat (DB13729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Camostat Mesylate 200 mg x 3 daily for 4 days.
Trial: NCT05684705
Drug: BV100
RxNorm normalized name: Bempedoic Acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous infusion
Trial: NCT06752135
Drug: neoadjuvant chemotherapy (cisplatin or carboplatin plus paclitaxel)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received three cycles of platinum-based neoadjuvant chemotherapy (cisplatin or carboplatin plus paclitaxel), followed by imaging to assess treatment response.
Trial: NCT04874831
Drug: domatinostat in combination with avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: domatinostat tablets and avelumab infusion
Trial: NCT05133674
Drug: Tamoxifen 20 mg
RxNorm normalized name: tamoxifen 20 MG
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: i) a self-testing capillary kit, the rhelise™ kit for measuring the concentrations of tamoxifen, 4-hydroxytamoxifen and Z-endoxifen and ii) a patient interactive digital tool (app) mBraze to collect data about symptoms and guide breast cancer patients on adjuvant tamoxifen.
Trial: NCT06035978
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebivolol (Nebilet) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
Trial: NCT06035978
Drug: Valsartan and Sacubitril
RxNorm normalized name: valsartan and sacubitril
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan and Sacubitril (Entresto) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
Trial: NCT06035978
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol (Dilatrend) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
Trial: NCT06035978
Drug: Bisoprolol
RxNorm normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bisoprolol (Concor) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
Trial: NCT06035978
Drug: Metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol (Betaloc ZOK) tablet will be administered orally to patients according to their clinical condition and the decision of the attending physician.
Trial: NCT05799755
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nintedanib 150 mg BID
Trial: NCT05662527
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One dosage of 4mg/kg (maximum of 400mg)
Trial: NCT05022212
Drug: LACTIN-V
RxNorm normalized name: Lactin-V
DrugBank: Lactobacillus crispatus strain CTV-05 (DB19093)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered vaginally
Trial: NCT05478252
Drug: Semaglutide J
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will initially receive 0.25 mg subcutaneous injections of semaglutide J OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
Trial: NCT05478252
Drug: Semaglutide B
RxNorm normalized name: Semaglutide Bulk powder
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will initially receive 0.25 mg subcutaneous injections of semaglutide B OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
Trial: NCT06599684
Drug: INV-102
RxNorm normalized name: INV-REMDESIVIR
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.7% Ophthalmic Solution
Trial: NCT06602479
Drug: MEDI0618
DrugBank: MEDI0680 (DB15768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI0618 per protocol
Trial: NCT06752811
Drug: paclitaxel polymeric micelles for injection
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel polymeric micelles for injection at a dose of 300 mg/m2 (based on body surface area), administered on Day 1, with intravenous infusion for ≥ 3 hours, every 3 weeks as a cycle.
Trial: NCT06752811
Drug: Gemcitabine Hydrochloride for Injection
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subjects also need to receive intravenous infusion of gemcitabine hydrochloride combination therapy at a dose of 1000 mg/m2 (based on body surface area), administered at D1 and D8 every 3 weeks.
Trial: NCT06752811
Drug: Paclitaxel for Injection (albumin bound )
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients in the control group will receive intravenous infusion of paclitaxel for Injection (albumin bound ) at a dose of 125 mg/m2 (based on body surface area), administered at D1, D8, and D15, every 4 weeks as a cycle.
Trial: NCT06752811
Drug: Gemcitabine Hydrochloride for Injection
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subjects also need to receive intravenous infusion of gemcitabine hydrochloride combination therapy at a dose of 1000 mg/m2 (based on body surface area), administered at D1, D8, and D15 every 4 weeks.
Trial: NCT05293574
Drug: norethisterone acetate
RxNorm normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethindrone, a progesterone agonist
Trial: NCT05753098
Drug: estrogen therapy
RxNorm normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral estradiol valerate
Trial: NCT05753098
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDE5 inhibitor
Trial: NCT05753098
Drug: Clomiphene Citrate 50mg
RxNorm normalized name: CLOMIPHENE CITRATE 50MG TAB
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: used for ovulation induction
Trial: NCT06672068
Drug: TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TY-9591 80mg QD+pemetrexed 500mg/m²（D1，Q3w）+Carboplatin AUC5/ Cisplatin 75mg/m²（D1，Q3w\*4 cycles）
Trial: NCT06672068
Drug: TY-9591 160mg QD+pemetrexed+Cisplatin/Carboplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TY-9591 160mg QD+pemetrexed 500mg/m²（D1，Q3w）+Carboplatin AUC5/ Cisplatin 75mg/m²（D1，Q3w\*4 cycles）
Trial: NCT06673290
Drug: Sirolimus (RAPAMUNE)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Use of different doses of the same drug
Trial: NCT05381974
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-Label
Trial: NCT01184287
Drug: Ranpirnase
RxNorm normalized name: Ranpirnase
DrugBank: Ranpirnase (DB04950)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycles 3 and until patient progression, on days 1,8 and 15 in a 21 day cycle
Trial: NCT06764056
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants receiving this intervention will be starting with a dose of semaglutide 0.25 mg. Physicians will follow Wegovy® Dosing Schedule guidelines, ending with a final dose of 2.4 mg at the fifth month. Type 2 diabetes participants wishing to stop at 1.0 mg will be allowed.
Trial: NCT05152680
Drug: [14C]-NV-5138
DrugBank: NV-5138 (DB19180)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, given as oral solution, 1600 mg
Trial: NCT06764368
Drug: Adebrelimab + Apatinib
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction Phase:~Subjects will receive Adebrelimab (1200 mg, Day 1) + Etoposide (100 mg/m2, Days 1-3) + Carboplatin (AUC = 4-5, Day 1) / Cisplatin (75 mg/m2, Day 1) (as determined by the investigator) + Apatinib (250 mg, orally, once daily) in 3-week cycles (Q3W) for 4 to 6 cycles.~Maintenance Phase:~Adebrelimab (1200 mg, Day 1) + Apatinib (250 mg, orally, once daily) will be administered for 1 year or until one of the following occurs: disease progression, intolerable toxicity, withdrawal of informed consent by the subject, voluntary withdrawal from the study, or other protocol-specified reasons.
Trial: NCT06763302
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The FDA has approved blinatumomab for post-consolidation treatment in all Ph-negative B-ALL cases, regardless of MRD status. Considering the high cost of blinatumomab and the financial burden on families, we aim to precisely identify the population who would benefit from blinatumomab and provide appropriate treatment.
Trial: NCT00002397
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002397
Drug: Saquinavir
RxNorm normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002397
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002397
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06763744
Drug: P2Y12 antagonist monotherapy
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CYP2C19 genetic testing is performed before discharge after stent insertion. Depending on the test results, rapid (CYP2C19\*1/\*17 or \*17/\*17) or normal (CYP2C19\*1/\*1) metabolizers are treated with clopidogrel monotherapy, and intermediate or poor metabolizers (with CYP2C19\*2 or \*3 alleles) are treated with potent P2Y12 inhibitors (prasugrel or ticagrelor) monotherapy.
Trial: NCT06763744
Drug: clopidogrel + aspirin
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In this group, a potent P2Y12 inhibitor was changed to clopidogrel (un-guided) 1 month after PCI with maintenance of co-prescription of aspirin (DAPT).
Trial: NCT06763029
Drug: Irinotecan liposomes combined with cetuximab + vermofenib
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vermofenil 960mg orally twice daily; Irinotecan liposomes, 70mg/m2, d1, 90 min intravenously, Q2W; Cetuximab 500mg/m2, d1, Q2W;
Trial: NCT06764628
Drug: SHR-4375
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-4375 injection
Trial: NCT06763328
Drug: Extended Release Metformin Hydrochloride
RxNorm normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT06766591
Drug: Ivonescimab combined with chemotherapy
RxNorm normalized name: miconazole
DrugBank: Ivonescimab (DB18931)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ivonescimab combined with chemotherapy. The specific chemotherapy regimen is based on the real world.
Trial: NCT06764940
Drug: Utidelone
RxNorm normalized name: Utidelone
DrugBank: Utidelone (DB17575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utidelone 30 mg/m2/d i.v, once a day for 5 consecutive days, every 21 days as a treatment cycle.
Trial: NCT04912596
Drug: Albuterol Sulfate inhalation aerosol 108 mcg per actuation
RxNorm normalized name: albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: equal to albuterol 90 mcg/puff, MDI
Trial: NCT04912596
Drug: Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: equal to albuterol 90 mcg/puff, MDI
Trial: NCT05731843
Drug: Cohort 1 BEM + Ruzasvir
RxNorm normalized name: Ruzasvir
DrugBank: Ruzasvir (DB11713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1 to 6 BEM under fasting conditions. Days 7 to 12 of BEM and Ruzasvir coadministered under fasting conditions. Days 13 to 18 of BEM and Ruzasvir coadministered under fed conditions
Trial: NCT06015893
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly subcutaneous (s.c.) injections of semaglutide (or placebo) up to 2.4 mg/week or maximum tolerated dose (MTD).
Trial: NCT06762548
Drug: DA-007
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical α1 agonist combination of Phenylephrine + Tyramine + Synephrine
Trial: NCT06760520
Drug: Ivonescimab (SMT112 or AK112) Injection
RxNorm normalized name: edaravone
DrugBank: Ivonescimab (DB18931)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eligible subjects will receive short-course radiotherapy (SCRT), 25Gy/5f/1 week. 1-2 weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK112 20 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 850-1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
Trial: NCT05731843
Drug: Cohort 2 Ruzasvir + BEM
RxNorm normalized name: Ruzasvir
DrugBank: Ruzasvir (DB11713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1 to 6 of Ruzasvir under fasting conditions. Days 7 to 12 of Ruzasvir and BEM coadministered under fasting conditions. Days 13 to 18 of Ruzasvir and BEM coadministered under fed conditions